Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later
暂无分享,去创建一个
Matthew W. Johnson | R. Griffiths | U. McCann | R. Griffiths | W. Richards | R. Jesse | Mw Johnson | W. A. Richards | U. Mccann
[1] W. Pahnke. LSD and Religious Experience , 2010 .
[2] J. Choksy. Research in the Social Scientific Study of Religion , 2010 .
[3] D. Hay. The Psychology of Religion: An Empirical Approach (3rd edn.), by Bernard Spilka, Ralph W. Hood Jr., Bruce Hunsberger and Richard Gorsuch. New York: Guilford, 2003. 671pp., hbk. ISBN 9781572309012. , 2009 .
[4] R. Griffiths,et al. Human hallucinogen research: guidelines for safety , 2008, Journal of psychopharmacology.
[5] Felix Hasler,et al. Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans , 2007, Psychopharmacology.
[6] R. Piedmont. Cross-cultural generalizability of the Spiritual Transcendence Scale to the Philippines: Spirituality as a human universal , 2007 .
[7] R. Griffiths,et al. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance , 2006, Psychopharmacology.
[8] Felix Hasler,et al. Modulating the Rate and Rhythmicity of Perceptual Rivalry Alternations with the Mixed 5-HT2A and 5-HT1A Agonist Psilocybin , 2005, Neuropsychopharmacology.
[9] J. C’de Baca,et al. Quantum change: ten years later. , 2004, Journal of clinical psychology.
[10] A. Forcehimes. De profundis: spiritual transformations in Alcoholics Anonymous. , 2004, Journal of clinical psychology.
[11] Felix Hasler,et al. Acute psychological and physiological effects of psilocybin in healthy humans : a double-blind , placebo-controlled dose – effect study , 2004 .
[12] H. Isbell,et al. The effect of N,N-dimethyltryptamine in human subjects tolerant to lysergic acid diethylamide , 1964, Psychopharmacologia.
[13] H. Isbell. Comparison of the reactions induced by psilocybin and LSD-25 in man , 2004, Psychopharmacologia.
[14] H. Isbell,et al. Comparison of psilocin with psilocybin, mescaline and LSD-25 , 2004, Psychopharmacologia.
[15] D. Cella,et al. Measuring spiritual well-being in people with cancer: The functional assessment of chronic illness therapy—spiritual well-being scale (FACIT-Sp) , 2002, Annals of behavioral medicine : a publication of the Society of Behavioral Medicine.
[16] P. Watson,et al. Dimensions of the Mysticism Scale: Confirming the Three‐Factor Structure in the United States and Iran , 2001 .
[17] R. Hood,et al. An empirical test of the unity thesis: The structure of mystical descriptors in various faith samples. , 2000 .
[18] R. Hébert,et al. Criterion Validity of a New Measure of Self-Actualization , 1999, Psychological reports.
[19] R. Piedmont. Does Spirituality Represent the Sixth Factor of Personality? Spiritual Transcendence and the Five-Factor Model , 1999 .
[20] E. Gouzoulis-Mayfrank,et al. Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers Results of an experimental double-blind placebo-controlled study , 1999, Psychopharmacology.
[21] J. Halpern,et al. Do hallucinogens cause residual neuropsychological toxicity? , 1999, Drug and alcohol dependence.
[22] Andreas Bäbler,et al. Psilocybin induces schizophrenia‐like psychosis in humans via a serotonin‐2 agonist action , 1998, Neuroreport.
[23] M. Mangini,et al. Treatment of alcoholism using psychedelic drugs: a review of the program of research. , 1998, Journal of psychoactive drugs.
[24] A Dittrich,et al. The Standardized Psychometric Assessment of Altered States of Consciousness (ASCs) in Humans , 1998, Pharmacopsychiatry.
[25] H. D. Abraham,et al. The Psychopharmacology of Hallucinogens , 1996, Neuropsychopharmacology.
[26] Peter C. Hill,et al. The psychology of religion: An empirical approach, 4th ed. , 1996 .
[27] P. Stamets. Psilocybin mushrooms of the world : an identification guide , 1996 .
[28] R. R. Abidin. Psychological Assessment Resources , 1995 .
[29] R. Kellner,et al. Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale. , 1994, Archives of general psychiatry.
[30] David Watson,et al. The PANAS-X manual for the positive and negative affect schedule , 1994 .
[31] P. Costa,et al. Revised NEO Personality Inventory (NEO-PI-R) and NEO-Five-Factor Inventory (NEO-FFI) , 1992 .
[32] R. Doblin. PAHNKE'S "GOOD FRIDAY EXPERIMENT' A LONG-TERM FOLLOW-UP AND METHODOLOGICAL CRITIQUE , 1991 .
[33] W. James. Varieties of Religious Experience , 2008 .
[34] Peter C. Hill,et al. The psychology of religion : an empirical approach , 1986 .
[35] J. Ott. The Wondrous Mushroom: Mycolatry in Mesoamerica , 1981 .
[36] R. Yensen,et al. The Peak Experience Variable in DPT-Assisted Psychotherapy with Cancer Patients , 1977 .
[37] O. McCabe,et al. Residential psychedelic (LSD) therapy for the narcotic addict. A controlled study. , 1973, Archives of general psychiatry.
[38] S. Grof,et al. LSD in the Treatment of Alcoholics , 1971 .
[39] W. Pahnke. Psychedelic drugs and mystical experience. , 1969, International psychiatry clinics.
[40] Pahnke Wn. Psychedelic drugs and mystical experience. , 1969 .
[41] W. Richards,et al. LSD-assisted psychotherapy with terminal cancer patients. , 1969, Current psychiatric therapies.
[42] G. H. Litwin,et al. REACTIONS TO PSILOCYBJN ADMINISTERED IN A SUPPORTIVE ENVIRONMENT , 1963, The Journal of nervous and mental disease.
[43] Hollister Le. Clinical, biochemical and psychologic effects of psilocybin. , 1961 .
[44] L. Hollister. Clinical, biochemical and psychologic effects of psilocybin. , 1961, Archives internationales de pharmacodynamie et de therapie.
[45] N. Smart,et al. Mysticism and Philosophy. , 1963 .
[46] C. R. Atwell,et al. Experimental psychiatry. V. Psilocybine, a new psychotogenic drug. , 1960, The New England journal of medicine.
[47] S. Malitz,et al. Some observations on psilocybin, a new hallucinogen, in volunteer subjects. , 1960, Comprehensive psychiatry.
[48] C. Smith,et al. Use of d-lysergic acid diethylamide in the treatment of alcoholism. , 1959, Quarterly journal of studies on alcohol.